Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Beats Estimates By $0.31 EPS

Praxis Precision Medicines (NASDAQ:PRAX) released its quarterly earnings data on Monday. The company reported ($3.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.54) by $0.31, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• Praxis said FDA discussions for ulixacaltamide are advanced and focused largely on labeling; management expressed strong confidence in approval around January and said it is preparing to launch promptly.
• Ulixacaltamide could require DEA scheduling, which management said may take about three months and prevent the company from shipping the drug until finalized. Praxis is arguing for no scheduling, but the outcome remains uncertain.
• The review of relutrigine appears less advanced than ulixacaltamide’s: FDA questions were discussed at the late-cycle meeting, leaving more uncertainty ahead of the December 27 PDUFA date, though Praxis said no information requests are currently pending.
• The EMERALD study has completed its last patient visits, but Praxis did not give a precise readout date, citing extensive data checks. Management voiced strong confidence in the study, while results have not yet been disclosed.
• Praxis reported $1.3 billion in cash and said its runway extends into 2028, including planned launches and pipeline investment. It also expects EMBRAVE3 to potentially support an elsunersen NDA and said the POWER2 study is underway, with POWER3 planned to start next year.

Praxis Precision Medicines Stock Up 0.1%

Praxis Precision Medicines stock traded up $0.49 during mid-day trading on Tuesday, hitting $333.46. 55,222 shares of the company were exchanged, compared to its average volume of 466,398. Praxis Precision Medicines has a 1-year low of $160.11 and a 1-year high of $392.70. The business has a fifty day moving average of $291.50 and a 200 day moving average of $313.82. The company has a market capitalization of $9.31 billion, a PE ratio of -25.79 and a beta of 2.85.

Trending Headlines about Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis reported a third-quarter loss of $3.23 per share, narrower than analysts’ expected loss of $3.54. The company also issued a corporate update alongside its results. Corporate update and third-quarter results Earnings information
• Positive Sentiment: Analyst coverage was supportive: BTIG reaffirmed its “buy” rating with an $826 price target, and a separate report put the average analyst target at $630.42. These targets suggest substantial upside from the prices cited in the reports. Analyst average price target
• Negative Sentiment: A report characterized PRAX as expensive relative to its book value, highlighting a valuation concern that could temper investor enthusiasm. Valuation relative to book value

Wall Street Analysts Forecast Growth

PRAX has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $582.00 price target on shares of Praxis Precision Medicines in a research note on Thursday, September 24th. Wall Street Zen lowered Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Robert W. Baird set a $514.00 target price on shares of Praxis Precision Medicines in a research report on Friday, August 7th. The Goldman Sachs Group reiterated a “buy” rating and set a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Finally, Wells Fargo & Company reduced their price objective on Praxis Precision Medicines from $362.00 to $343.00 and set an “equal weight” rating for the company in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $629.42.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity.

Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions.